During January 2021, the chronic therapy segment continued to deliver a healthy growth performance while acute segments reported a subdued performance, leading to overall lower sales growth in January 2021 than December 2020 sales, understands India Ratings and Research (Ind-Ra). During April 2020 to January 2021, the average price growth and new product launches growth stood at 4.7% and 2.7% yoy, respectively while average volume growth fell 6.5% yoy, which led to average India’s pharmaceutical market’s (IPM) size growing 1% yoy.
Chronic
Segment Reported Healthy Growth during Pandemic: Continued-though-lower
growth was seen in chronic and sub-chronic segments at 6.1% yoy (December 2020:
10.9% yoy) and 8.6% yoy (9.7%), respectively, in January 2021. acute segment grew
just 1.1% yoy in January 2021 (December 2020: 6.0%). During April 2020 to
January 2021, the average monthly growth of chronic, sub-chronic and acute
segment was 7.1%, +2.0% and negative 3.4% yoy, respectively. Ind-Ra highlights
that the acute segment reported negative growth between April to August 2020 on
account of COVID-19 while a gradual improvement has started since September
2020.
Top
Five Therapies Contribution stood at 57% of IPM:
These therapies are cardiac (chronic; 14% of IPM), anti-infectives (acute;
13%), gastro-intestinal (acute; 11%), anti-diabetic (chronic; 10%) and vitamins
(acute; 9%).
|
Figure 3 |
|||||||
|
Therapy/group names; INR million |
MAT |
Growth |
% total |
Jan 21 |
Jan 20 |
Jan 19 |
Jan 18 |
|
Cardiac |
2,02,235 |
13.2 |
13.9 |
17,689 |
16,258 |
14,688 |
12,798 |
|
Statins |
20,217 |
9.0 |
10.0 |
1,710 |
1,687 |
1,508 |
1,401 |
|
Angiotensin Ii
Antagonists + Diuretics |
16,297 |
9.8 |
8.1 |
1,367 |
1,331 |
1,237 |
1,078 |
|
Angiotensin-Ii
Antagonists, Plain |
15,694 |
11.0 |
7.8 |
1,321 |
1,275 |
1,155 |
1,006 |
|
Beta-Blocking
Agents, Plain |
15,081 |
9.9 |
7.5 |
1,319 |
1,235 |
1,138 |
1,029 |
|
Platelet
Aggregation Inhibitors |
14,581 |
9.4 |
7.2 |
1,272 |
1,184 |
1,087 |
963 |
|
Anti-Infectives |
1,88,058 |
-2.8 |
12.9 |
15,400 |
15,825 |
14,819 |
14,026 |
|
Cephalosporins |
59,828 |
-13.9 |
31.8 |
4,783 |
5,373 |
4,922 |
4,901 |
|
Broad-spectrum Penicillin |
25,891 |
-11.9 |
13.8 |
2,174 |
2,610 |
2,404 |
2,291 |
|
Antivirals,
Excluding HIV Products |
18,326 |
72.8 |
9.7 |
1,196 |
912 |
1,008 |
830 |
|
Macrolides and Similar
Types |
17,375 |
0.9 |
9.2 |
1,363 |
1,509 |
1,372 |
1,258 |
|
Systemic Agents
for Fungal Infections |
15,388 |
-10.9 |
8.2 |
1,379 |
1,367 |
1,255 |
1,164 |
|
Gastro Intestinal |
1,62,974 |
3.5 |
11.2 |
14,576 |
12,750 |
12,196 |
11,029 |
|
Gastroprokinetics |
36,387 |
6.8 |
22.3 |
3,263 |
2,852 |
2,691 |
2,426 |
|
Anti-Ulcerants
Acid Pump Inhibitors |
20,403 |
5.5 |
12.5 |
1,780 |
1,664 |
1,485 |
1,338 |
|
Intestinal
Anti-Infective Antidiarrhoeals |
10,531 |
-6.6 |
6.5 |
974 |
857 |
832 |
751 |
|
Antidiarrhoeal
Micro-Organisms |
9,784 |
-13.2 |
6.0 |
947 |
854 |
848 |
690 |
|
Hepatic
Protectors, Lipotropics |
8,744 |
9.3 |
5.4 |
720 |
629 |
580 |
544 |
|
Anti Diabetic |
1,48,671 |
7.7 |
10.2 |
12,766 |
12,120 |
11,299 |
9,415 |
|
Oral
Antidiabetics |
1,16,085 |
8.0 |
78.1 |
9,964 |
9,380 |
8,706 |
7,300 |
|
Human Insulin
Premix |
10,253 |
1.8 |
6.9 |
870 |
886 |
875 |
740 |
|
Insulin
Analogues Basal |
8,208 |
13.1 |
5.5 |
706 |
665 |
614 |
504 |
|
Insulin
Analogues Premix |
4,206 |
1.5 |
2.8 |
366 |
357 |
358 |
292 |
|
Insulin
Analogues Rapid |
3,069 |
11.3 |
2.1 |
280 |
246 |
224 |
170 |
|
Vitamins/Minerals/Nutrients |
1,30,277 |
7.0 |
8.9 |
11,028 |
9,827 |
9,084 |
8,306 |
|
Calcium
Products |
23,299 |
-1.2 |
17.9 |
1,975 |
1,904 |
1,791 |
1,624 |
|
Traditional
Antioxidants (Multivit/Multimineral) |
20,350 |
18.1 |
15.6 |
1,675 |
1,324 |
1,248 |
1,173 |
|
Other Vitamins |
19,022 |
16.1 |
14.6 |
1,562 |
1,329 |
1,228 |
1,078 |
|
B Complex |
14,256 |
6.9 |
10.9 |
1,145 |
1,044 |
931 |
873 |
|
Methylcobalamin
Combinations |
9,245 |
-2.1 |
7.1 |
779 |
747 |
734 |
655 |
|
Source: AIOCD-AWACS,
Ind-Ra |
|||||||
|
Figure 4 |
||||||||||||
|
Therapy |
Feb 20 |
Mar 20 |
Apr 20 |
May 20 |
Jun 20 |
Jul 20 |
Aug 20 |
Sep 20 |
Oct 20 |
Nov 20 |
Dec 20 |
Jan 21 |
|
Anti-Infectives |
14.3 |
10.4 |
-21.6 |
-20.8 |
-9.7 |
-10.1 |
-11.0 |
1.5 |
6.7 |
0.2 |
5.2 |
-2.7 |
|
Cardiac |
14.4 |
21.7 |
7.8 |
5.4 |
14.8 |
13.6 |
11.6 |
17.5 |
19.7 |
8.7 |
14.9 |
8.8 |
|
Gastro Intestinal |
11.5 |
8.1 |
-14.0 |
-11.4 |
1.8 |
-1.5 |
-2.4 |
5.9 |
14.0 |
3.1 |
16.2 |
14.3 |
|
Anti Diabetic |
11.9 |
19.5 |
7.7 |
2.2 |
9.6 |
6.4 |
1.6 |
6.7 |
9.8 |
1.9 |
9.9 |
5.3 |
|
Vitamins |
12.0 |
4.8 |
-16.1 |
-8.3 |
6.0 |
5.9 |
6.4 |
16.5 |
22.7 |
6.6 |
14.0 |
12.2 |
|
Derma |
10.3 |
-1.5 |
-22.6 |
-10.5 |
3.2 |
-0.9 |
-1.2 |
3.4 |
10.3 |
1.4 |
10.8 |
9.1 |
|
Respiratory |
18.8 |
24.5 |
0.9 |
-4.7 |
5.0 |
-1.7 |
-12.3 |
-10.3 |
-6.5 |
-6.9 |
-8.7 |
-14.1 |
|
Pain/Analgesics |
11.8 |
4.8 |
-20.0 |
-16.9 |
-1.5 |
-6.3 |
-9.5 |
-4.0 |
2.9 |
-5.2 |
6.0 |
5.0 |
|
Neuro/CNS |
11.0 |
10.9 |
-3.2 |
0.9 |
9.5 |
4.0 |
-0.2 |
5.4 |
9.8 |
0.3 |
9.2 |
6.7 |
|
Gynaecological |
7.3 |
-3.7 |
-23.4 |
-17.5 |
-3.4 |
-5.0 |
-5.6 |
-2.1 |
6.6 |
-4.3 |
6.6 |
6.9 |
|
Anti-Neoplastics |
2.9 |
-15.2 |
-13.2 |
-15.4 |
-12.6 |
-1.6 |
-2.9 |
5.4 |
2.8 |
0.1 |
8.1 |
-2.6 |
|
Blood Related |
21.2 |
5.4 |
-12.7 |
-7.2 |
0.8 |
-3.1 |
-1.9 |
-5.8 |
-8.1 |
-9.0 |
6.6 |
3.3 |
|
Hormones |
13.8 |
9.8 |
-6.1 |
-7.4 |
3.1 |
2.7 |
-2.1 |
3.7 |
9.0 |
-3.4 |
6.0 |
0.8 |
|
Ophthal |
8.3 |
-4.8 |
-29.0 |
-20.4 |
-7.0 |
-11.1 |
-13.0 |
-5.4 |
0.1 |
-11.4 |
-2.3 |
-1.0 |
|
Vaccines |
16.1 |
-6.3 |
-22.0 |
-10.3 |
3.7 |
-2.9 |
-5.2 |
5.5 |
14.7 |
8.2 |
4.3 |
-7.7 |
|
Urology |
14.7 |
10.3 |
-9.6 |
-4.9 |
5.8 |
5.9 |
7.6 |
12.6 |
17.0 |
9.7 |
16.0 |
13.7 |
|
Source: AIOCD-AWACS, Ind-Ra |
||||||||||||
|
Figure 5 |
|||||||
|
Company/Therapy; INR million |
MAT Jan 21 |
Growth yoy |
% total |
Jan 21 |
Jan 20 |
Jan 19 |
Jan 18 |
|
Cardiac |
|||||||
|
Sun |
21,418 |
7.6 |
10.6 |
1,800 |
1,748 |
1,675 |
1,611 |
|
Torrent |
14,655 |
11.1 |
7.2 |
1,264 |
1,198 |
1,056 |
897 |
|
Lupin |
14,089 |
11.3 |
7.0 |
1,235 |
1,186 |
1,039 |
874 |
|
USV |
9,961 |
12.8 |
4.9 |
870 |
812 |
703 |
612 |
|
Cipla |
9,905 |
14.1 |
4.9 |
822 |
778 |
715 |
614 |
|
Anti-Infectives |
|||||||
|
Alkem |
18,085 |
-7.7 |
9.6 |
1,480 |
1,534 |
1,462 |
1,366 |
|
Aristo |
16,568 |
1.0 |
8.8 |
1,259 |
1,231 |
1,077 |
980 |
|
Cipla |
16,507 |
14.2 |
8.8 |
1,387 |
1,220 |
1,176 |
1,079 |
|
Mankind |
12,374 |
-5.2 |
6.6 |
931 |
1,033 |
943 |
897 |
|
Macleods |
11,159 |
-4.6 |
5.9 |
938 |
948 |
880 |
879 |
|
Gastro Intestinal |
|||||||
|
Abbott |
16,812 |
11.1 |
10.3 |
1,545 |
1,292 |
1,151 |
1,043 |
|
Sun |
14,104 |
3.1 |
8.7 |
1,299 |
1,185 |
1,108 |
1,037 |
|
Alkem |
9,596 |
7.8 |
5.9 |
838 |
719 |
761 |
623 |
|
Dr. Reddy’s |
7,864 |
0.9 |
4.8 |
717 |
626 |
582 |
479 |
|
Aristo |
7,649 |
19.1 |
4.7 |
658 |
522 |
468 |
389 |
|
Anti Diabetic |
|||||||
|
Abbott |
17,749 |
2.6 |
11.9 |
1,520 |
1,514 |
1,505 |
1,224 |
|
USV |
14,637 |
6.3 |
9.8 |
1,234 |
1,178 |
1,123 |
1,006 |
|
Lupin |
13,914 |
10.8 |
9.4 |
1,236 |
1,105 |
1,005 |
784 |
|
Sun |
11,392 |
6.7 |
7.7 |
957 |
939 |
875 |
817 |
|
Sanofi India |
9,922 |
5.5 |
6.7 |
817 |
833 |
791 |
629 |
|
Vitamins/Minerals/Nutrients |
|
|
|
|
|
|
|
|
Abbott |
11,192 |
21.6 |
8.6 |
926 |
774 |
717 |
648 |
|
Mankind |
8,380 |
6.3 |
6.4 |
690 |
584 |
554 |
520 |
|
Alkem |
7,385 |
18.4 |
5.7 |
636 |
477 |
508 |
427 |
|
Torrent |
5,873 |
9.3 |
4.5 |
493 |
437 |
392 |
337 |
|
Sun |
5,262 |
15.0 |
4.0 |
469 |
386 |
342 |
309 |
|
Source: AIOCD-AWACS, Ind-Ra |
|||||||
Note: Sun = Sun
Pharmaceutical Industries Ltd; Torrent Pharma = Torrent Pharmaceuticals Ltd
(IND AA/Stable); Lupin = Lupin Ltd; Alkem = Alkem Ltd (IND A1+); USV = USV Ltd;
Cipla = Cipla Ltd (IND AAA/Stable); Mankind = Mankind Pharma Ltd; Abbott Labs =
Abbott Laboratories Ltd; Dr. Reddy’s Labs = Dr. Reddy’s Laboratories (IND
AA+/Stable); Sanofi India = Sanofi India Ltd; Macleods = Macleods
Pharmaceuticals Ltd; Aristo = Aristo Pharmaceuticals Private Limited
NLEM: Drug price control has
been a source of considerable agony to the Indian pharmaceutical industry. National
List of Essential Medicines (NLEM) in India, which determines the basis of drug
price regulation, consists around 14% of the total IPM.
SOLICITATION DISCLOSURES
Additional information is available at www.indiaratings.co.in.
Ratings are not a recommendation or suggestion, directly or indirectly, to you or any other person, to buy, sell, make or hold any investment, loan or security or to undertake any investment strategy with respect to any investment, loan or security or any issuer.
DISCLAIMER
ALL CREDIT RATINGS ASSIGNED BY INDIA RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTPS://WWW.INDIARATINGS.CO.IN/RATING-DEFINITIONS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE WWW.INDIARATINGS.CO.IN. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. INDIA RATINGS’ CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE.